Pfizer's BRAFTOVI Boosts PFS, Achieves 64.4% ORR; FDL 5.87%
Pfizer's BRAFTOVI regimen showed statistically significant progression-free survival improvement and achieved a 64.4% confirmed ORR versus 39.2% standard therapy in Cohort 3 of its Phase 3 BREAKWATER trial. With Pfizer representing 5.87% of FDL's holdings, these results could materially impact the ETF's performance.
1. BREAKWATER Trial Topline Results
Pfizer's BRAFTOVI regimen demonstrated a statistically significant improvement in progression-free survival for metastatic colorectal cancer patients with the BRAF V600E mutation in Cohort 3 of the Phase 3 BREAKWATER trial.
2. Objective Response Rate Gains
The combination of Braftovi, cetuximab and FOLFIRI achieved a confirmed objective response rate of 64.4% versus 39.2% for standard-of-care FOLFIRI with or without bevacizumab (odds ratio 2.76, p=0.001), building on overall ORR improvements of 60.9% vs. 40.0%.
3. Impact on FDL Holdings
Pfizer comprises 5.87% of FDL’s portfolio, so these positive clinical results may drive Pfizer shares higher and boost the ETF’s returns if they translate into regulatory approval and commercial uptake.